First recorded at the fourth annual IO Combinations 360° conference, this panel moderated by Dr Daniel Chen, IGM Biosciences discusses advancing bispecifics for combination immunotherapy. This discussion covers the following topics:

What are the types of bispecifics and what are the limitations?
What are the toxicity related side effects?
What are teh next steps/levels for bispecifics?
What does the future hold for bispecifics?

Panelists include:

Julie Bailis, PhD, Amgen
Rajkumar Ganesan, PhD, Janssen Research & Development
David Schaer, PhD, Pfizer

To learn more about the 5th annual IO Combinations 360° conference please visit www.iocombinations360.com

Advancing Bispecifics for Combination Immunotherapy

Share

Embed